Among the additional validation cohort with HCC patients treated with anti-PD/PD-L1, NAFLD was independently associated with shortened survival of patients with HCC after anti-PD-1/PD-L1 treatment. The gene discussed is CD274; the disease is metabolic dysfunction-associated steatotic liver disease.